Decision: Favourable
Study Title:
A Phase 3, Randomized, Placebo-Controlled, Double-Blind,Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NREC Code:
23-NREC-CT-005
Decision:
Favourable
Meeting Date:
25/01/2023
Study Type:
CT application
Principal Investigator:
Dr Dearbhaile Collins
PI Institution:
Cork University Hospital
Sponsor:
Karyopharm Therapeutics Inc.,